The controversies of parabens – an overview nowadays by ZVONIMIR PETRIC et al.
17
Acta Pharm. 71 (2021) 17–32 Review
https://doi.org/10.2478/acph-2021-0001
The controversies of parabens – an overview nowadays
Effects of paraben toxicity, i.e., endocrine-disruption proper-
ties, are in the focus of researchers for decades, but still – 
they are a hot subject of debate. Parabens are aliphatic es-
ters of p-hydroxybenzoic acid, which are widely used as 
antimicrobial agents for the preservation of cosmetics, 
pharmaceuticals and foods. Mostly used parabens are 
 methyl-, ethyl-, propyl- and butylparaben. Although the 
toxicity of parabens is reported in animals and in in vitro 
studies, it cannot be taken for granted when discussing 
hazards for human health due to an unrealistic exposure - 
-safety profile. Many studies have demonstrated that para-
bens are non-teratogenic, non-mutagenic, non-carcinogenic 
and the real evidence for their toxicity in humans has not 
been established. For now, methyl-, ethyl- and propyl-
paraben are considered safe for use in cosmetics and pharma-
ceuticals within the recommended range of doses. Regarding 
alternatives for parabens, a variety of approaches have 
been proposed, but every substitute would need to be tested 
rigorously for toxicity and safety.
Keywords: parabens, toxicity, safety, endocrine disruption, 
health risk
INTRODUCTION
Human health depends on homeostasis where hormones as chemical messengers, 
regulate many physiological functions. Such regulation is defined and organised on the 
molecular and biochemical levels. In recent times, numerous publications reported side-
effects of various xenobiotics, i.e., chemical compounds from the environment which can 
directly modulate hormonal homeostasis and signalling. This certainly raises the question 
of the safety and extent of human exposure to the chemicals, which are classified as endo-
crine-disrupting chemicals (EDCs) (1). According to the World Health Organization 
(WHO), EDCs are substances that are mostly man-made, found in various materials such 
as pesticides, metals, additives or contaminants in food, and personal care products. EDCs 
have been suspected to be associated with altered reproductive function in males and 
 females, increased incidence of breast cancer, abnormal growth patterns and neurodevelop-




1 Unit of Pharmacokinetics and Drug 
Metabolism, Department of Pharmacol-
ogy at the Institute of Neuroscience and 
Physiology Sahlgrenska Academy at the 
University of Gothenburg, 40 530 
Göteborg, Sweden
2 Independent Unit of Toxicology 
University of Zagreb Faculty of 
Pharmacy and Biochemistry 
10 000 Zagreb, Croatia
Accepted March 8, 2020
Published online April 2, 2020
* Correspondence; e-mail: izuntar@pharma.hr; petric.zvonimir@gmail.com
18
Z. Petric et al.: The controversies of parabens – an overview nowadays, Acta Pharm. 71 (2021) 17–32.
 
 examples of low dose effect endocrine-disrupting chemicals and one of them is the group 
of parabens (3). Parabens, a group of esters of p-hydroxybenzoic acid that are used as 
 antifungal and antibacterial agents, are widely used in personal care products (PCPs), 
foodstuffs, pharmaceuticals and various types of cosmetics (4, 5).
As some scientific studies linked endocrine-disruption with parabens, widely used as 
a preservative for more than 70 years, parabenophobia started to spread around the globe. 
Sometimes media and press made things worse because of their mostly high influence on 
public opinion. Such a bad reputation of parabens resulted that nowadays some people are 
buying only paraben-free products, without actually thinking what is used as an alternative. 
Bearing in mind medical and health professionals who are daily confronted with 
suspicions about parabens safety and evidence of their proven toxicity (6, 7), it is important 
to approach to this controversial topic cum grano salis and highlight from toxicological and 
pharmacological aspect what we know so far, and if we should be worried. These topics of 
current knowledge of parabens are focused on and discussed in this review.
WHAT ARE PARABENS AND WHAT IS THEIR USE?
Parabens are aliphatic esters of p-hydroxybenzoic acid (pHBA) (Fig. 1) widely used as 
preservatives in cosmetics, pharmaceuticals and the food industry. In cosmetics, they are 
mostly found in topical preparations, while in pharmaceuticals they are part of various 
formulations (Table I). Mostly used parabens are methyl-, ethyl-, propyl- and butylparaben. 
Earlier, due to their antimicrobial efficacy, parabens were found in injections and ophthal-
mic preparations while today such use is reduced to avoid potential irritations (8).
Parabens are chemically stable and effective over a wide pH range, with wide antimi-
crobial activity, particularly against Gram-positive bacteria and fungi (including molds). 
Parabens are odourless and tasteless, which also makes them highly preferred (8). In the 
past, quality, efficacy and safety were investigated only for an active pharmaceutical in-
gredient (API), whereas today the efficacy and safety of any excipient, including parabens, 
must be investigated and monitored by International Pharmaceutical Excipients Council 
(IPEC) (9).
Antimicrobial activity of parabens increases with the length of their aliphatic chain, 
from methylparaben to butylparaben. Chain length has an impact on their solubility, which 
decreases as the length of the aliphatic chain increases, but that is overcome by using different 
salts of parabens. The stability of parabens is markedly decreased in the presence of  non-ionic 
surfactants, like polysorbate 80. Moreover, there have been observed incompatibilities with 
some other compounds such as hydroxypropyl cellulose, methylcellulose, bentonite, magne-
sium trisilicate, talc, tragacanth, sodium alginate, sorbitol and atropine. Hence, to achieve 
Fig. 1. Structures of common p-hydroxybenzoic acid (pHBA) esters, i.e., parabens (8).
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better antimicrobial efficacy, parabens are often used in combination with other antimicrobial 
agents. Also, as parabens are aliphatic esters of pHBA, their hydrolysis can occur in formula-
tion itself, which consequently affects the antimicrobial activity (8).
It is important to mention that parabens were never declared to be allergenic or carci-
nogenic, although sporadic cases of hypersensitivity reactions, like contact dermatitis were 
reported, while immediate reactions with urticaria and bronchospasm have occurred rarely. 
In the latest edition of the Handbook of Pharmaceutical Excipients (8), parabens are classi-
fied as non-teratogenic, non-mutagenic and non-carcinogenic. It is worth mentioning that 
parabens are naturally present in some foods (fruits and vegetables) and white wine in very 
low concentrations, thus making paraben intake from plant sources negligible (10, 11).
“STIRRING THE POT”
After isolation of parabens in cancerous breast tissue by Darbre et al. (12) parabens 
became the focus of research for many scientists, consequently tagging them to be bad. 
Further discoveries of parabens in various biological samples, such as urine, blood, semen, 
adipose tissue, placenta, amniotic fluid and breast milk, only made matters worse (13–15), 
despite the fact that based on the available repeated-dose toxicity studies, repeated oral 
exposure to methyl-, ethyl- or propylparaben is not considered to cause serious effects to 
health (16–18).
What should be addressed from the start is that scientific studies which point parabens 
as EDCs, mostly have an oral route of exposure, while the topical route is less prevalent (19). 
The topical route should not be neglected, because numerous cosmetic and pharmaceutical 
preparations are used only in that way, which makes the interpretation of the paraben 
safety-exposure profile over-exaggerated and unreal. Additionally, successful translation 
of paraben toxicity data from animals to humans, or extrapolation from in vitro to in vivo, is 
quite questionable as well in terms of providing truthfulness (20). Having that in mind, one 




Injections (i.m., i.v., s.c.) 0.065–0.25 0.005–0.2
Inhalation solutions 0.025–0.07 0.015
Intradermal injections 0.10 0.02–0.026
Nasal solutions 0.033 0.017
Ophthalmic preparations 0.015–0.02 0.005–0.01
Oral solutions and suspensions 0.015–0.02 0.01–0.02
Rectal preparations 0.1–0.18 0.02–0.1
Topical preparations 0.02–0.3 0.01–0.6
Vaginal preparations 0.1–0.18 0.02–0.1
i.m. – intramuscular, i.v. – intravenous, s.c. – subcutaneous
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question arises: is reported toxicity of parabens and endocrine disruption, clearly and un-
deniably linked with health hazards in humans? Well, according to the provided informa-
tion based on scientific papers and presented in this review, the answer is — no.
Namely, Darbre et al. (12) investigated the assumption that creams and lotions, con-
taining parabens as preservatives and used under the armpits and breasts, could increase 
the incidence of breast cancer in women. After breast tumour tissue analysis, results re-
vealed that methylparaben was most prevalent in the analyzed tissue samples (among 
ethyl-, propyl-, butyl- and isobutylparaben).
Given its most common use as a preservative, this is not surprising at all, but before 
making any assumptions, a few facts should be considered for a valid conclusion. What 
should have been done is finding the route by which parabens entered the body at the first 
place, and how they accumulated in breast tissue because they could also enter by con-
suming food. Moreover, the medical history of patients was not known, neither was the 
breast tumour type. Was that estrogen receptor-positive breast cancer? It is not known. 
Most importantly, there were no control tissues, and parabens were found in samples of 
tissue used as a blank. Also, the sample size is a very important parameter during every 
experiment in order to achieve statistical strength.
BIOTRANSFORMATION, PHARMACODYNAMICS AND BIOMONITORING OF PARABENS
Paraben biotransformation studies reported that more than 90 % of parabens are  excreted 
in the urine as conjugates (glucuronide and sulphate conjugates), whereas only a small 
fraction is left unconjugated (21). It is also considered that conjugated parabens have no 
biological activity (21, 22). The penetration of parabens through the skin varies, and also 
shows the difference between species (16–18). Additionally, only up to 0.9 % of the topi-
cally applied propylparaben (to the whole human body) could be recovered in the urine in 
a free form (19). The explanation for this lies in variable lipophilicity of parabens which 
increases as aliphatic chain becomes longer, variable thickness of the skin layers and the 
solvents used in formulation, limited duration of exposure, relatively small amount of the 
product itself, and the presence of the esterase in the skin which hydrolyzes parabens. 
Parabens absorbed from the oral route of exposure, or by the skin, are hydrolyzed to pHBA 
and p-hydroxyhipuric acid (pHHA) (19). pHHA is a biotransformation product of parabens 
found in animals and humans. Humans even produce pHHA endogenously, as a product 
of tyrosine metabolism (23).
Shin et al. (21) developed a propylparaben (PP) pharmacokinetic model, which can 
also be used as a tool for pharmacokinetic and toxicokinetic assessments of other para-
bens. In brief, orally given PP was rapidly absorbed (< 2 h), and quickly and completely 
eliminated; terminal half-life, i.e., time taken to eliminate half of the remaining fraction of 
the substance in the body, was 2.9  h. pHBA, pHHA and free PP were eliminated even 
slightly faster than conjugated PP, while the oral PP bioavailability of 39 % (expressed as a 
fraction of the dose absorbed) is a rough estimate only.
Considering all of the above, it could be concluded that the degree of paraben absorp-
tion through the skin is not high and consequently bioavailability is expected to be low, 
whereas biotransformation data count against suggestions of paraben accumulation in the 
body. On the other hand, some data are indicating that in vivo dermal absorption of para-
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bens is more effective than it is claimed (24), while regarding in vitro dermal absorption 
studies, Scientific Committee on Consumer Safety (SCCS), consider that they have low 
scientific quality (16–18). Hence, there is absolutely a need for more pharmacokinetic and 
toxicokinetic studies, to give a definite answer on that matter.
Additionally, new data for total daily exposure to parabens (via foodstuffs, cosmetics 
and pharmaceuticals) based on the measurement of real samples in Chinese females (25), 
report exposure to be 0.326 mg kg–1 daily, which is much less than the previous results 
provided by Soni et al. (10), of 1.26 mg kg–1 daily.
The classic premise in toxicology the dose makes the poison, cannot be applied to EDCs, 
because their pharmacological effect is not governed by a typical mechanism of receptor-
mediated action. In other words, even the smallest dose of EDC can show effect like cell 
proliferation, whereas a higher dose may have the opposite effect – inhibition of cell 
growth. The latter has been shown for phytoestrogens, but never for parabens. Moreover, 
in vitro assay with radiolabeled estradiol (³H-estradiol), designed to measure a competitive 
estrogen receptor (ER) inhibition, showed that concentration of parabens should be several 
orders of magnitude larger than estradiol to have any effect on the ER. The explanation lies 
in the fact that parabens have a lower binding affinity for the ER (1).
It is generally accepted that in vitro chemical safety testing methods and animal labo-
ratory data offer the potential for efficient and economical tools to provide relevant assess-
ments of human health risk. However, simple extrapolation is not possible. It was stated 
that there is a need to refine currently available in vitro to in vivo extrapolation (IVIVE) 
approaches before they can be utilized for regulatory decision-making (26). It was pro-
posed to combine in vivo and ex vivo studies of paraben toxicity to build more comprehen-
sive, scientifically sound strategies for paraben safety testing (27).
Analysis of human urine reflects directly the exposure to parabens and serves as a 
good method of biomonitoring from time to time. One such study revealed that parabens 
are detected in 99 % of the American population. From the whole group of mostly used 
parabens, methyl- and propylparaben were the most frequently detected ones. After sta-
tistical stratification, interesting results showed up: women had a 3-fold higher value of 
methylparaben and a seven-fold higher value of propylparaben, compared to men. Fur-
thermore, the black population had a greater exposure compared to white, and most im-
portantly, no differences in health status among subjects were observed (28). Despite para-
ben detection in urine, the authors agree that the measurable level of parabens in urine 
does not immediately imply a risk for human health (28, 29). Additionally, parabens have 
been detected in human matrices such as breast tumour, seminal plasma, adipose tissue, 
human breast milk, placenta and cord blood (12, 30–34) showing the general population is 
inevitably exposed to parabens in daily life.
PARABENS AND REPORTED FINDINGS OF THEIR TOXICITY  
– TWO SIDES OF THE SAME COIN
For a long time, parabens were considered harmless and therefore they have been 
widely used as preservatives. However, over 20 years, a vivid discussion on paraben safety 
is ongoing because of the main concern from their endocrine-disrupting potential.
As stated previously, parabens do have estrogenic activity in vitro, but it is very low. 
Although estrogenic activity increases with the length of paraben’s aliphatic chain, its 
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relevance relies on the fact that methyl-, ethyl-, propyl- and butylparaben have 2.5 × 106, 
1.5 × 105, 3 × 104 and 1 × 104 times lower potency than estradiol, the physiological agonist for 
ER (35). Moreover, their low estrogenic activity and a high tendency for hydrolysis were 
already confirmed (36, 37).
The mechanism of xenoestrogenicity of parabens is not well understood. Paraben 
esters are rapidly metabolized in vivo to the relatively inactive metabolite pHBA, and to 
what extent micromolar concentrations of parabens disturb normal estrogen activity or 
function as mimicker in vivo is unknown (38). One hypothesis relates the potential biologic 
activity to the inhibition of the enzymatic activity of 17β-hydroxysteroid dehydrogenase 
type 2 (estrogen and androgen-converting enzyme), at micromolar concentrations that 
would increase conversion of estradiol to the weaker estrone (20). Another study found 
that parabens inhibit aromatase, an enzyme involved in a rate-limiting step in steroi-
dogenesis, by one order of magnitude less than that which induces MCF-7 human breast 
cancer cell line proliferation, potentially indicating a more potent antiestrogenic effect (39). 
It was shown that isopropyl-, butyl- and benzylparaben are aromatase inhibitors, but such 
inhibition required micromolar paraben concentration which is several orders of magni-
tude higher than the concentration (in nmol L–1) previously found in human breast tissue 
(40). Hence, toxicological relevance cannot be determined.
The study of paraben effects on mRNA levels and protein expression of ER-α (ESR1) 
and ER-β (ESR2) and the progesterone receptor (PGR) conclude that, via these effects on 
hormone receptor expression and stimulation, the estrogenic effect of parabens and puta-
tive initiation and progression of breast cancer may be explained (41).
Estrogenic activity of parabens in vivo was assessed by monitoring the enlargement of 
female rat uterus. After orally (or s.c.) administered methyl- and butylparaben for three 
days, it was observed that neither methylparaben (up to 800 mg kg–1 daily) nor butylpara-
ben (up to 1200 mg kg–1 daily) caused enlargement of the uterus when given orally. How-
ever, after s.c. administration of butylparaben at doses of 600–800 and 1200 mg kg–1 daily, 
uterine enlargement was 30–40 % and 70 %, resp. (35, 40). If these data were translated to 
the human, an equivalent dose of parabens is not realistic.
In a study where methyl-, propyl- and butylparaben were orally administered to female 
rats for 5 weeks (100 mg kg–1 daily), results showed that parabens accelerated ovarian 
 dysfunction (previously induced by another chemical) and disrupted folliculogenesis and 
steroidogenesis, i.e., induced premature ovarian failure (42). For humans, such exposure is 
not of toxicological relevance according to established No Observed Adverse Effect Level 
(NOAEL) of 1000 mg kg–1 b.m. daily for methyl- and ethylparaben by the European Food 
Safety Authority (EFSA) and the Scientific Committee Consumer Safety (SCCS); this was 
done based on the absence of reproductive effects from four repeated-dose toxicity studies. 
Propylparaben is not allowed as a food additive in the EU and more data is needed for its 
NOAEL. But, in the meantime, the SCCS proposes that the NOEL for butylparaben of 2 mg 
kg–1 b.m. daily can be very conservatively used for propylparaben (16–18).
Another study associated the menstrual cycle duration with parabens exposure. Re-
sults showed that a shorter menstrual cycle is associated with higher parabens measured in 
the urine (43). However, the subjects were asked to keep a diary for recording their menstrual 
bleeding on their own, which could affect statistics. A mechanism for the observed relation-
ship between menstrual cycle length and exposure to parabens could not be explained and 
subjects with smaller intra-individual variability of cycle duration seemed to be exposed to 
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higher levels of parabens, for which the underlying mechanism of the relationship was not 
clear either. The authors concluded that they might have failed to also include some other 
potential covariates (like psychological stress) in addition to sample size (43).
Oishi et al. studied the effects of butylparaben (44) and propylparaben (45) on the male 
reproductive system. In brief, rodent males (rats and mice) 4–6 weeks old were fed with 
parabens up to 15, 150 and 1500 mg kg–1 daily, for 4 weeks. The study consisted of measuring 
sperm production, sperm reserve, masses of epididymis, testicles and prostate, and the lev-
el of testosterone. The lowest intake of parabens did not show any effects, whereas higher 
intake decreased testosterone in both species. Furthermore, rats with the highest intake of 
butylparaben had a 15 % decrease of epididymis mass, while mice had a 15 % increase (44). 
Such deviation in the results is not explained by the authors, so the valid conclusions cannot 
be drawn. Additionally, high doses of parabens used in this study are unrealistic in terms 
of exposure for humans, so toxicological importance of these data, again, cannot be given. 
Most importantly and interesting, Hoberman et al. (46) performed the same experiment and 
concluded that there were no changes in testosterone levels, spermatogenesis, nor were any 
effects dependent on doses of parabens. Furthermore, testosterone levels and measurement 
of sperm concentration in Hoberman’s study were consistent with the historical National 
Toxicology Program (NTP) data, while in Oishi’s study (44) testosterone was 4–5 times higher, 
along with a deviation in sperm concentration as well.
Although theoretical concerns regarding paraben activity and xenoestrogenicity are 
supported by a body of in vitro and animal in vivo evidence, the actual impact, if any, to 
human health is far from clear, especially given the margin of exposure safety data (margin 
of exposure/margin of safety, MOE/MOS) (16–18). Thus, it is not surprising that there are 
no studies in humans confirming the harmful effects of paraben exposure from the estrogen 
mimicry standpoint (38).
One might surely ask themself, what about reported evidence of paraben’s carcino-
genicity and genotoxicity in some studies?
Since the first detection of parabens in human breast tumour tissue in 2004 (12) with 
many recognized shortcomings, recent in vitro short-term and long-term studies per-
formed on human breast lines exposed to parabens reported that parabens can influence 
not only proliferation but also migratory and invasive properties of human breast cancer 
lines (47). Recently, the review paper summarised current evidence data of environmental 
chemicals, termed obesogens, that may be able to interfere in the endocrine regulation of 
energy metabolism and adipose tissue structure. This paper confirmed the obesogenic 
potential of parabens and offered a possible explanation of why obesity is an underlying 
risk factor for so many diseases including cancer (48). However, current scientific know-
ledge is insufficient to demonstrate a clear cancer risk due to the topical application of 
cosmetics that contain parabens on normal intact skin (38).
From the available in vivo carcinogenicity studies on methyl-, ethyl- and propylpara-
ben it can be concluded that they are not considered to be carcinogenic (8, 10, 16, 17, 22).
The results of the in vivo studies are equivocal in terms of the potential of parabens to 
exhibit harmful effect in the animals, but on the other hand, in vitro data on cultured human 
peripheral lymphocytes from Bayülken et al. (49, 50) showed that parabens are cytotoxic and 
genotoxic, which may indicate also a genotoxic potential for humans. Taken altogether, in vitro 
studies often have a big impact on providing a piece of new knowledge, but solely they cannot 
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be used as a reference point, hence scientific community hopes that more studies in future will 
provide new and stronger insights about paraben genotoxicity and carcinogenicity.
Concerning reproductive male and female health, recently contradictory results were 
presented. Smarr et al. (51) suggested that specific urinary parabens found in consumers’ 
goods (methyl-, ethyl- and butylparaben) may adversely impact sperm quality parameters 
among reproductive-age male partners of couples trying for pregnancy. Also, a positive 
association of couples’ urinary concentration of parabens (methyl- and ethyl-) in the con-
text of reduced fecundity was obtained (52) while the other study showed no relationship 
between urinary paraben concentrations (methyl-, ethyl- and butyl-) and in vitro fertilisa-
tion outcomes among women undergoing infertility treatments (53).
It was stated that medications are among the three major sources of paraben. In oral 
pharmaceutical formulations, methylparaben and propylparaben prevail (Table I) whereas 
other parabens are also used to a lesser extent, such as ethylparaben and butylparaben. 
The latter is predominantly used in pharmaceutical formulations for the cutaneous route 
(8, 54). The contribution of medicinal products to aggregate exposure could be estimated 
only very roughly and worst-case for methyl- and propylparaben. For ethylparaben, there 
was insufficient data available to estimate the contribution by medicinal products to total 
exposure (16, 17). Dodge et al. (55) showed that paraben-containing medicines contributed 
to higher urinary paraben concentrations within hours of use which is in agreement with 
data from the National Health and Nutrition Examination Survey (NHANES) 2005–2006 
showing that nearly all subjects had detectable levels of methyl- and propylparaben in 
their urine, while only 40 % of subjects had detectable levels of butylparaben (56). Despite 
this, data from NHANES 2005–2012 showed no clear overall evidence of the association 
between the use of paraben-containing medications and increases in urinary paraben con-
centrations among participants in NHANES 2005–2012. Therefore, the authors pointed out 
that these results highlight the difficulties inherent in the proper assessment of exposures 
with short half-lives based on a single cross-sectional biologic sample (57).
Considering that humans are often exposed to a mixture of chemicals rather than a 
single compound, nowadays, particular interest is given to realistic scenarios of exposure 
to chemical cocktails in which parabens, as a type of EDC, interact with other types of 
chemicals with a possible synergistic or additive effect (38, 39, 58).
ARE PARABENS NECESSITY FOR CHILDREN? 
WHAT ABOUT ALTERNATIVES AND REGULATORY OPINION?
Parabens are used in different applications as preservatives. Therefore, there is a large 
overlap of their use in cosmetics, food, cleaning products and pharmaceuticals as well as in 
regards to available alternatives. In EU parabens are regulated by the cosmetics regulation 
(59), the food additives regulation (60) and the detergents directive (61). They are allo wed in 
the EU for use in pharmaceuticals and monographs can be found within the autho ritative 
source of information, The Handbook of Pharmaceutical Excipients (8) which is an interna-
tionally accepted comprehensive guide to uses, properties and safety of exci pients.
The SCCS carried out a case-by-case safety assessment of the different parabens. 
While the safety for use in cosmetics of certain types of parabens (methyl-, ethyl-, propyl- 
and butylparaben) has been confirmed by the SCCS, the SCCS could not rule out the risk 
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for human health of other categories of parabens (isopropyl-, isobutyl-, phenyl-, benzyl- 
and pentylparaben) (62). For general cosmetic products containing parabens, excluding 
specific products for the nappy area, the SCCS considers that there is no safety concern in 
children (any age group) as the MOS value was based on very conservative assumptions, 
both concerning toxicity and concerning exposure (29, 62). The European Medicines Agency 
(EMA) claims that methylparaben up to 0.2 % in oral formulations is not dangerous, 
 including children of any age (54). Moreover, methyl- and propylparaben in concentrations 
of up to 0.1 % have a GRAS (Generally Recognized as Safe) status in the USA (8). Risk 
 assessments on parabens have been performed by several European expert panels includ-
ing the European Food Safety Authority (EFSA) and SCCS. EFSA established a full-group 
acceptable daily intake (ADI) of 0–10 mg kg–1 b.m. for the sum of methylparaben, ethyl paraben 
and propylparaben. The EFSA opinion dated July 2004 considered that propylparaben 
should not be included anymore in this group ADI due to effects on the male reproductive 
organs observed in juvenile rats and the lack of a clear NOAEL. As a consequence, from 
the year 2006, propylparaben was no longer allowed for use as a food additive within 
the European Union (54, 63). EU authorities, as a measure of precaution, limited some 
parabens in products intended for the diaper area for children under 3 years, whereas 
methyl- and ethylparaben are considered safe. Additionally, the EU allows the use of a 
single paraben in the concentration of 0.4 %, or 0.8 % in combination (54). As a precautionary 
measure, the rule of thumb should always be to use the lowest amount of any excipient, 
not just parabens.
The fetus, neonates and young children are considered to be most vulnerable to EDC 
exposures, drug treatments and the effects of active compounds and excipients present in 
pharmaceutical and other products due to their unique physiology (16–18, 64–66). That is, 
indeed, the rationale behind the EU decision to ban parabens in products intended to be 
applied to intertriginous areas in children younger than 3 years.
Recently, it was stated that the unborn fetus will be better protected from possible 
parabens effects than the neonate/newborn or early infant exposed dermally to parabens 
by the more efficient systemic parabens inactivation by the mother (29). However, the 
study that reported the levels of major parabens in the first urine of newborn infants (67) 
and cord blood of mother-child pairs (34) indicated evidence of fetus exposure and trans-
placental passage of parabens. The study of Park et al. (68) showed that the estimated daily 
intake of parabens in infants via breastfeeding appears to be negligible when compared to 
the acceptable daily intake values (ADI of total parabens, 0–10 mg kg–1 daily) set forth by 
the EFSA (63). However, considering the vulnerability of breastfed infants and ubiquitous 
sources of exposure from daily use of household and personal toiletries, efforts to identify 
sources and mitigate exposure are warranted.
The safety assessment of parabens present in pediatric oral pharmaceutical formula-
tions needs to take into account their beneficial antimicrobial effects, so their withdrawal 
may increase the risk of infection in neonates (64). However, paraben’s maximum daily 
 intake, or exposure profile, is quite difficult to determine in this case, since the products do 
not indicate which amount of the specific excipient was used. Furthermore, while acceptable 
daily intake has been established for adults (54, 63), this has not been assigned to neonates. 
It is difficult to extrapolate data to neonates because of differences in their metabolism and 
changing physiology. Yakkundi et al. (69) showed the presence of parabens in the blood 
circulation of 196 neonates from the UK and Estonia and confirmed a systemic exposure to 
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these compounds following administration of routine medicines: this is of concern, being 
the exposure at high doses associated to hyperbilirubinemia and oestrogenic effects (70).
Hence, the best solution for avoiding systemic exposure to any preservative, not just 
parabens, is the use of single-dose containers (64). On the other hand, to avoid “harmful” 
parabens, the cosmetic industry uses alternatives. How can we be sure they are better and 
safer, compared to thoroughly studied parabens?
Methylisothiazolinone (MI), as a paraben alternative, is used due to a strong biocidal 
effect. MI has been associated with high cytotoxic effects in vitro and is characterized as an 
allergen causing hypersensitivity (71). However, SCCS concluded that the concentration of 
MI of 15 ppm is safe and restricted its use in rinse-off products, whereas in leave-on products 
use of MI is prohibited (72). Another commonly used paraben alternative is triclosan (TCS). 
In some studies, topically applied TCS caused only mild irritation, whereas the others 
were reported for hepatotoxicity and liver damage, but such adverse effects have not been 
reported in humans (73). Just from the two previous examples, it is obvious that using 
parabens alternatives does not immediately imply safety and a better choice.
Additionally, the SUBSPORTplus Portal as a result of the SUBSPORT multicentric project 
financed partially by EU and with the participation of European Chemicals Agency 
(ECHA), national EU agencies concerning food, health and environment, partners from 
industry and independent non-profit organisations that advocate for substitution of toxic 
chemicals to safer alternatives, published a document, Specific Substances Alternatives 
Assessment  – Parabens, that is mainly concentrated on the cosmetic use of parabens (74). 
This document gave a summarized profile of safety and toxicity data of possible paraben 
alternatives as well as further assessed data (pros and cons for different aspects: health, 
environmental, performance and cost) for chemicals (phenoxyethanol, sorbic acid, benzoic 
acid) that passed the set criteria.
A variety of approaches have been proposed to find alternatives for parabens, includ-
ing, but not limited, to citrus extracts such as ascorbic acid, benzyl alcohol, synergistic 
blends of multifunctional natural ingredients including botanical extracts, honeysuckle 
extract, spice extracts, fragrances, the replacement of the aqueous component of creams 
with Aloe vera and single-use packaging system for products. Pure essential oils, such as 
rosemary, lavender, clove, and plant extracts such as Calendula, exhibit variable microbio-
static and microbicidal activities (38, 64, 74). Herbal preservatives and essential oils are 
generally considered as safe even for children, but regarding the toxicity of some oils, 
Eisenhut (75) pointed out that essential oils cannot be recommended for use in food preser-
vation because like any artificial food additive, every component would need to be tested 
rigorously for toxicity before its contact with food for human consumption could be 
 permitted. The same stands for cosmetics and recently the European Directorate for the 
Quality of Medicines and HealthCare of the Council of Europe published Guidance on 
 Essential Oils in cosmetic products dealing with toxicity and safety of essential oils (76).
Overall conclusion regarding paraben alternatives is in line with a recent paper by 
Fransway et al. (38) which pointed out that having to remove parabens from consumer 
products could result in their substitution with alternatives that are less proven and pos-
sibly unsafe. The fact is that compiled data of paraben dermal toxicity have not shown their 
significant toxicity, thus eventual withdrawal from consumer products is not based on 
scientific knowledge.
27
Z. Petric et al.: The controversies of parabens – an overview nowadays, Acta Pharm. 71 (2021) 17–32.
 
CONCLUSIONS
Parabens are widely used and efficient preservatives. Their toxic effects, endocrine 
disruption, carcinogenicity or genotoxicity was never confirmed in humans. Furthermore, 
their affinity for estrogen receptors is from 2.5 million- to 10,000- times less compared to 
estradiol.
Although theoretical concerns regarding paraben activity, xenoestrogenicity and tox-
icity are supported by a body of in vitro and animal in vivo evidence, the actual impact, if 
any, to human health is far from clear. Also, findings of parabens in the human tissue and 
fluids showed no conclusive evidence of paraben-related toxicity, nor undoubtedly causal 
relationship was established. Careless removal of parabens from consumer products with 
alternative substitutes which are less investigated, possibly toxic or unsafe, can lead to 
serious adverse effects and human health risks.
As scientific evidence of paraben toxicity and endocrine disruption in humans is still 
missing, parabens remain to be considered safe. But, regarding safety as well as the toxic-
ity of parabens, precautions should be considered because some doubts exist and still lack 
complete scientific knowledge. However, more research is needed to overcome scientific 
gaps and controversy about them in order to provide more accurate answers to unsolved 
questions, even when just potential concerns may arise.
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